Advertisement

Topics

Alnylam Announces Successful Outcome Following FDA Type A Meeting to Discuss Fitusiran Program in Hemophilia

16:00 EST 9 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
− Alignment Reached with FDA on Amended Safety Measures and Risk Mitigation Strategy to Enable Resumption of Fitusiran Clinical Program − − Reinitiation of Dosing Targeted Around Year-End − Alnylam Ph...

Other Sources for this Article

Alnylam Pharmaceuticals, Inc.
Investors and Media
Christine Regan Lindenboom, 617-682-4340
or
Investors
Josh Brodsky, 617-551-8276

NEXT ARTICLE

More From BioPortfolio on "Alnylam Announces Successful Outcome Following FDA Type A Meeting to Discuss Fitusiran Program in Hemophilia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...